Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canada Decides Against Suffix-Based Biologics Naming System

Executive Summary

Following a consultation with stakeholders, the Canadian regulator says identification of biologics using their brand and non-proprietary names has emerged as the most preferred option as it is consistent with current practice.

You may also be interested in...

US Must Rethink Biologic Naming Suffix, Says IGBA

In the wake of a decision by Health Canada not to implement a suffix to non-proprietary names to distinguish biosimilars from their branded counterparts, the IGBA has urged the FDA to reconsider the US approach.

Canada Gears Up For Expected Rise In Biosimilar Filings

Efforts are under way in Canada to strengthen the regulator’s ability to evaluate the growing number of biosimilar filings, and to increase confidence in the biosimilar regulatory framework through targeted outreach and education activities.

Australia Says No To ‘Complex’ US-Style Suffixes For Biologicals

Australia's Therapeutic Goods Administration wants to avoid the complexity and potential confusion associated with the introduction of a suffix-based system for naming biological medicines. The TGA has instead decided to supplement its existing naming convention for biologicals with a strengthened framework for reporting adverse events.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts